Skip to main content

Table 1 Demographic characteristics of participants

From: Clinical significance of focal ß-amyloid deposition measured by 18F-flutemetamol PET

 No-FMM uptake (n = 174)Focal-FMM uptake (n = 53)Diffuse-FMM uptake (n = 83)p
No vs focal uptake
p
No vs diffuse uptake
p
Focal vs diffuse uptake
Age (mean ± SD)69.4 ± 8.673.5 ± 7.971.4 ± 8.50.0080.2530.494
Men (%)73 (42.0)15 (28.3)37 (44.6)0.0750.6920.058
Education, years (mean ± SD)10.7 ± 5.010.3 ± 5.011.0 ± 4.51.0001.0001.000
APOE ε4 carrier (%)21/166 (12.7)23/53 (43.4)42/81 (51.9)< 0.001< 0.0010.340
Disease duration (months) (Mean ± SD)62.5 ± 52.950.3 ± 44.541.5 ± 41.60.4550.0091.000
Vascular risk factors
 Hypertension (%)80 (46.0)23 (43.4)29 (34.9)0.7420.0950.324
 Diabetes (%)33 (19.0)5 (9.4)11 (13.3)0.1040.2570.502
 Hyperlipidemia (%)57 (32.8)18 (34.0)11 (13.3)0.8710.0010.004
 Cognitive level   < 0.001< 0.001< 0.001
 CU (%)102 (58.6)17 (32.1)6 (7.2)   
 MCI (%)64 (36.8)20 (37.7)41 (49.4)   
 ADD (%)8 (4.6)16 (30.2)36 (43.4)   
  1. Abbreviations: FMM 18F-flutemetamol, APOE ε4 Apolipoprotein ε4, CU cognitively unimpaired, MCI mild cognitive impairment, ADD Alzheimer’s disease dementia